spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare News Roundup: Biopharmaceutical

 HSMN NewsFeed - 18 Jun 2021
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jun 2021
Irrimax Receives FDA Clearance for Irrisept(R) as an Antimicrobial Wound Lavage for US Market
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jun 2021
Lilly Launches Think Talk Treat Migraine(TM) to Help Improve Diagnosis and Treatment of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jun 2021
Pharmaceutical Associates, Inc. appoints Dr. Suketu Sanghvi as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Jun 2021
Senda Biosciences Strengthens Leadership Team with Key Management Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2021
Aucta Pharma and Oakrum Pharma Announce Launch of Generic Version of JADENU(R) Sprinkle (Deferasirox Granules)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jun 2021
Senda Biosciences Announces Closing of $98 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jun 2021
Cardinal Health(TM) Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK(R) Pediatric Indication
Biopharmaceuticals Radiology Oncology FDA
 HSMN NewsFeed - 9 Jun 2021
MindMed Announces Chief Executive Officer Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2021
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2021
MorphImmune, Inc. Appoints Ronald Martell as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 1 Jun 2021
Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 1 Jun 2021
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2021
Betagenon AB announces new CEO and new Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2021
Vyluma Inc. Launches With Robust Opthalmic Portfolio, Leading With A Pharmaceutical Treatment In Phase III For Myopia
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 May 2021
Eliem Therapeutics Announces $60 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 May 2021
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
Biopharmaceutical Personnel
 HSMN NewsFeed - 18 May 2021
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 18 May 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 May 2021
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 May 2021
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2021
SpliSense Secures $28.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 May 2021
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 May 2021
Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for Tolmar's FENSOLVI(R) Effective July 1, 2021
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 May 2021
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 6 May 2021
Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 May 2021
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2021
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 5 May 2021
BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 May 2021
Astellas' XTANDI(TM) (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Apr 2021
Blue Therapeutics announces Series A raise
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Apr 2021
Capsida Biotherapeutics Debuts with $140 Million of Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Apr 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
Biopharmaceuticals FDA
Older Biopharmaceutical stories   Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.